Vancomycin IV — Competitive Intelligence Brief

Vancomycin IV (Vancomycin IV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glycopeptide antibiotic. Area: Infectious Disease.

marketed Glycopeptide antibiotic D-Ala-D-Ala peptidoglycan precursor Infectious Disease Small molecule

Target snapshot

Vancomycin IV (Vancomycin IV) — Debiopharm International SA. Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vancomycin IV TARGET	Vancomycin IV	Debiopharm International SA	marketed	Glycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursor
Administration of Vancomycin	Administration of Vancomycin	University of Colorado, Denver	marketed	Glycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursor
Dalbavancin via Intravenous Administration	Dalbavancin via Intravenous Administration	University of Colorado, Denver	marketed	Lipoglycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursors
Cefazolin / Vancomycin	Cefazolin / Vancomycin	University of Cincinnati	marketed	Beta-lactam antibiotic / Glycopeptide antibiotic	Penicillin-binding proteins / D-Ala-D-Ala peptidoglycan precursors
Vancomycin - model-based dosing regimen	Vancomycin - model-based dosing regimen	Murdoch Childrens Research Institute	marketed	Glycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursor
Vancomycin (POC)	Vancomycin (POC)	University of Maryland, Baltimore	marketed	Glycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursor
Vancomycin II	Vancomycin II	Wake Forest University Health Sciences	marketed	Glycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glycopeptide antibiotic class)

1. Clinica Universidad de Navarra, Universidad de Navarra · 2 drugs in this class
2. Memorial Sloan Kettering Cancer Center · 2 drugs in this class
3. Wake Forest University Health Sciences · 2 drugs in this class
4. VA Office of Research and Development · 1 drug in this class
5. Merck Sharp & Dohme LLC · 1 drug in this class
6. Murdoch Childrens Research Institute · 1 drug in this class
7. OrthoCarolina Research Institute, Inc. · 1 drug in this class
8. University of Colorado, Denver · 1 drug in this class
9. University of Maryland, Baltimore · 1 drug in this class
10. Debiopharm International SA · 1 drug in this class